Although pTau and Aβ are the most commonly used blood biomarkers for assessing amyloid pathologies and tauopathies in Alzheimer’s disease, recent studies have identified GFAP as a reliable alternative and potentially more sensitive indicator of pathological states. Here, GFAP is linked to Alzheimer disease.